Media

Corgentech to Present at JP Morgan H&Q; 21st Annual Healthcare Conference

Palo Alto, Calif., January 3, 2003 -- Corgentech Inc., a privately-held biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the JP Morgan H&Q 21st Annual Healthcare Conference. His presentation will be held on Monday, January 6 at 1:30 p.m. PST, in the Elizabethan C/D Room at The Westin St. Francis Hotel in San Francisco.

McLaughlin will provide an update on the company's progress on its lead product, E2F Decoy, which is being evaluated in two Phase III clinical trials for prevention of graft failure following coronary and peripheral bypass surgery. He will also discuss other projects in the company's expanding pipeline based on its novel and versatile research platform.

About Corgentech Inc.

CCorgentech Inc. is a privately-held biotechnology company that is the leader in the discovery, development and commercialization of an exciting and powerful new class of therapeutics called transcription factor decoys or TF Decoys. The Company's proprietary technology platform is capable of delivering multiple new product candidates to treat diseases that affect large patient populations in a relatively short period of time. Corgentech is based in Palo Alto, Calif. For more information on the company and its technology, visit www.corgentech.com.

Contacts:
Richard Powers Corgentech	Kristin Nash WeissCom Partners
650-624-9600 [email protected]	415-302-7951 [email protected]

Back to top